Approval · Notice of Compliance 35141 · 2025
DIPENTUM: Notice of Compliance 35141
Issued April 8, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35141
- Date
- April 8, 2025
- Company
- Searchlight Pharma Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in product ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIPENTUM | 02063808 | Marketed |
Medicinal ingredients
- OLSALAZINE SODIUM 250 MG per CAP